Shares of Globus Medical (GMED) soared 5.23% in after-hours trading on Thursday following the release of the company's second-quarter earnings report, which exceeded analyst expectations.

The musculoskeletal solutions company reported adjusted earnings per share of $0.86, significantly beating the analyst consensus estimate of $0.76. This represents a 14.67% increase from the same period last year. Globus Medical also outperformed on the revenue front, posting quarterly sales of $745.3 million, surpassing the analyst estimate of $741.8 million. The reported revenue marks an 18.37% increase compared to the previous year's second quarter.

Adding to investor optimism, Globus Medical reaffirmed its full-year 2025 guidance. The company maintained its revenue outlook of $2.80 billion to $2.90 billion and its non-GAAP EPS guidance of $3.00 to $3.30. This reaffirmation suggests confidence in the company's growth trajectory despite broader economic uncertainties. The strong quarterly performance, coupled with the maintained guidance, likely fueled the after-hours stock rally as investors responded positively to Globus Medical's robust financial health and growth prospects.